After two years of under-performance shares of Novartis (NVS) could be poised for gains going...

|About: Novartis AG (NVS)|By:, SA News Editor

After two years of under-performance shares of Novartis (NVS) could be poised for gains going into next year, according to Barron's. The report cites a promising pipeline of drugs, a 4% dividend and a below-market multiple, all of which should pay off handsomely over the near-term. Additionally, nearly 30% of the company's sales come from drugs that have come to market just since 2007, which Barron's attributes to the company's continued heavy investment into R&D, and is another element that adds to the stock's long-term attractiveness.